MedTrace Logo

Interleukin-6 and Thyroid Dysfunction in Hemodialysis Patients

NCT07328113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2026-01-08

No results posted yet for this study

Summary

Chronic kidney disease (CKD) is often associated with multiorgan complications, including thyroid hormone dysfunction. Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been proposed as a marker of inflammation that may contribute to these alterations. The main question it aims to answer is:

Is there an association between interleukin-6 and thyroid hormone dysfunction in patients with chronic kidney disease (CKD) Blood samples will be collected and analyzed from 65 patients who have undergone hemodialysis for at least 3 months.

Conditions

  • Chronic Kidney Disease on Hemodialysis
  • Thyroid Gland Disease

Interventions

DIAGNOSTIC_TEST

Thyroid hormone

Sampling was carried out using a consecutive sampling method, in which every patient who met the study criteria was included as a sample until the predetermined sample size was achieved. Patients who had been confirmed to meet the inclusion and exclusion criteria underwent blood collection of 10 mL (serum or plasma) prior to hemodialysis for the examination of complete blood count, BUN, creatinine, albumin, fasting blood glucose, IL-6, FT4, T3, FT3, T4, and TSH. The IL-6 level was measured using the Automatic Immunoassay Fluorescence method with the Automatic Fluorescence Immunoassay Analyzer Vazyme QD-S2000. Thyroid function tests (FT4, T3, T4, FT3, and TSH) were performed using the Enzyme-Linked Immunosorbent Assay (ELISA) method with Autobio Immunoassay reagents on the Autobio A1000 analyzer.

Sponsors & Collaborators

  • Universitas Airlangga Hospital, Surabaya

    collaborator UNKNOWN

  • Dr. Soetomo General Hospital

    lead OTHER_GOV

Principal Investigators

  • Sony Wibisono Mudjanarko, dr., Sp.PD, K-EMD, PhD · Dr. Soetomo General Hospital

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2024-03-31
Completion
2024-06-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07328113 on ClinicalTrials.gov